ArticleCell reports. Medicine2022
Artificial intelligence in breast cancer diagnostics.
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Fragmentomic liquid biopsy enables early breast cancer detection, molecular subtyping and lymph node assessment.Nature communications · 2026Article
- Artificial intelligence for triple-negative breast cancer from imaging to multi-omics.Frontiers in oncology · 2026Review
- Hollow MnOInternational journal of nanomedicine · 2026Article
- Decoding breast cancer imaging trends: the role of AI and radiomics through bibliometric insights.Breast cancer research : BCR · 2025Article
- Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis.Breast cancer research : BCR · 2024Review
- Artificial Intelligence for Precision Oncology of Triple-Negative Breast Cancer: Learning from Melanoma.Cancers · 2024Article
- Machine learning-based models for the prediction of breast cancer recurrence risk.BMC medical informatics and decision making · 2023Article
- The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial-Mesenchymal Transition.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since breast cancer deaths are mainly due to metastasis, predicting the risk that a primary tumor will develop metastasis after a first diagnosis is a central issue that could be addressed by artificial intelligence. To overcome the problem posed by limited availability of standardized datasets, algorithms should include biological insight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.